Redx Pharma (formed in September 2010) has three subsidiaries: Redx Oncology Ltd launched in April 2012, Redx Anti-Infectives Ltd launched in April 2013 and Redx Immunology Ltd launched in May 2015.
A drug discovery company focused on the development of proprietary, small molecule therapeutics in cancer, infection and autoimmune disease.
Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.
Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.
Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.